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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Expression of placenta growth factor (PlGF) mRNA is shown to correlate
with the progression and prognosis of several human cancers. In this study, we assessed
whether the PlGF mRNA level in oral squamous cell carcinoma (OSCC) tissue could be used
to predict the progression and prognosis of OSCCs in Taiwan.
Methods: This study used quantitative real-time reverse transcription-polymerase chain reaction
(quantitative RT-PCR) to detect the PlGF mRNA levels in 63 paired OSCC and adjacent normal-
looking oralmucosa (non-OSCC) tissues. Threshold cycle (CT)was defined as thePCRcycle number
needed to generate a pre-determined amount of DNA (threshold). For a chosen threshold, a smal-
ler starting copy number ofmRNA results in a higher CT value. In this study, the relative expression
level of tissue PlGFmRNA in eachOSCC patientswas expressed asDCTZ(OSCCCTe non-OSCC
CT). Thus, the higher the DCT, the greater the copy number of PlGF mRNA in tissues.
Results: We found that the higher mean PlGFmRNADCT value was significantly associated with
OSCCs with larger tumor size (pZ 0.03), positive lymph node metastasis (pZ 0.003), moreof Dentistry, National Taiwan University Hospital, Number 1, Chang-Te Street, Taipei 10048, Taiwan.
(M.Y.-P. Kuo).
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254 S.-J. Cheng et al.advanced clinical stages (pZ 0.013) or the presence of loco-regional recurrence (pZ 0.039).
Positive lymph nodemetastasis (pZ 0.019) andPlGFmRNADCT value>2 (pZ 0.016)were iden-
tified as two independent unfavorable prognosis factors bymultivariate analyses with Cox regres-
sion model. Moreover, Kaplan-Meier curve showed that OSCC patients with a PlGF mRNA DCT
value >2 had a significantly poorer recurrence-free survival than those with a PlGF mRNA DCT
value 2 (log-rank test, pZ 0.017).
Conclusion: TheOSCC tissue PlGFmRNA level canbeused to predict theprogression andprognosis
of OSCCs in Taiwan.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Oral squamous cell carcinoma (OSCC) is the eighth most
common cancer in the world and the most frequent
malignancy of the oral cavity.1 In Taiwan, OSCCs rank as the
sixth most prevalent cancer in both sexes and account for
the fourth most common cancers in men in 2010.2
Placenta growth factor (PlGF) is a member of the
vascular endothelial growth factor (VEGF) family, which is
related to angiogenesis and carcinogenesis.3 PlGF was
found to promote proliferation, differentiation, and
survival of endothelial cells by binding to VEGF receptor 1
(VEGFR1, also known as FLT1).3 Clinically, overexpressed
PlGF mRNA or protein level correlates with pathological
angiogenesis,3 tumor cell growth,4e6 positive lymph node
metastasis,4,7,8 advanced clinical stage,8e10 recurrence,7,11
and poor prognosis7,8,10 of a variety of cancers. Recently,
we reported that the higher mean PlGF labeling index
assessed by immunohistochemical staining and the higher
mean serum PlGF level measured by ELISA are significantly
associated with the more advanced progression and poorer
prognosis of OSCC.12,13
In this study, we evaluated whether the PlGF mRNA level
of OSCC surgical specimen measured by the quantitative
real-time reverse transcription-polymerase chain reaction
(quantitative RT-PCR) could be a valuable biomarker to
predict the therapeutic effect, progression, recurrence and
prognosis of OSCC.
Methods and materials
Patients and oral cancer specimens
This study has been reviewed and approved by the Insti-
tutional Review Board and an informed consent was ob-
tained from each patient before collection of surgical
samples. Sixty-three OSCC patients (59 men and four
women; mean age 56 years; range, 33e81 years) were
included in this study. Paired surgical samples were
collected from OSCC and adjacent normal-looking oral
mucosal (non-OSCC) tissues. All tissues were freshly
embedded in OCT compound, snap frozen, and kept at
80C until use. PlGF mRNA levels in both OSCC and non-
OSCC tissues were measured by quantitative RT-PCR.
Diagnosis of OSCC was based on histological examination
of hematoxylin and eosin-stained tissue sections.
All OSCC patients received total surgical excision of their
tumors plus either selective (39 patients) or radical neckdissection (24 patients) at the Department of Oral and
Maxillofacial Surgery, National Taiwan University Hospital,
Taipei, Taiwan during the period from January 2008 to
December 2011. Follow-up duration was defined as the
period between the operation date and day of the last visit,
according to the patient’s chart. If involved surgical
margin, perineural invasion or lymphovascular permeation
of OSCC, or extracapsular spread of metastatic cervical
lymph node were detected histologically, postoperative
concurrent chemoradiation therapies were also included in
the treatment protocol. In this study, four patients
received adjuvant radiotherapy and another 33 patients
received both radiotherapy and chemotherapy after
surgery. None of the patients had received any form of
tumor-specific therapy before total surgical excision of the
lesion. Of the 63 cases of OSCC, 23 were buccal mucosa, 19
tongue, 10 gingiva, six palate, and five floor of the mouth
cancers. Histologic features of OSCC were further classified
into three different types (well-, moderately-, and poorly-
differentiated OSCC). Of the 63 OSCC cases, there were 59
(94%) well- and four (6%) moderately differentiated OSCCs.
Clinical staging and TNM status of OSCCs at initial presen-
tation of the tumor were determined by clinical palpation,
head-and-neck magnetic resonance imaging (MRI), chest X-
ray, abdominal sonography, and the whole body bone scan
according to the guidelines from American Joint Committee
on Cancer (AJCC).14Patients’ oral habits
Details of patients’ oral habits, including daily/weekly
consumption of areca quid, cigarette, and alcohol as well
as the duration of these habits were recorded. OSCC
patients were defined as areca quid chewers when they
chewed two or more areca quids daily for at least 1 year, as
cigarette smokers when they smoked every day for at least
1 year and consumed more than 50 packs of cigarettes per
year, and as alcohol drinkers when they drank more than 4
days and consumed more than 20 g of pure alcohol per
week for at least 1 year. According to these definitions, 56
(88%) patients were areca quid chewers, 56 (88%) were
smokers, and 51 (81%) were drinkers. Furthermore, all of
our OSCC patients stopped chewing areca quids after
surgery, some of them stopped smoking completely after
surgery, and some of them continued to smoke with
a reduced number of cigarettes (<five cigarettes per day)
after surgery according to the inquisition from the patients
and their family members.
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polymerase chain reaction
Total cellular RNA was isolated using an RNA extraction kit
(Qiagen Inc., CA, USA) from tissue homogenized with
Trizol reagent (Invitrogen Inc., Carlsbad, Valencia, CA, USA)
as recommended by the manufacturers. The mRNA expres-
sion levels after each treatment were determined by quan-
titative RT-PCR using the TaqMan Gene Expression
Assays (Applied Biosystem, Foster City, CA, USA) for PlGF
(ID:Hs00182176_m1) and glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH; ID: Hs99999905_m1) on anABI Prism real-
time PCR system (Applied Biosystem) as previously
described.10 Threshold cycle (CT) is the fractional cycle
number at which the fluorescence generated by cleavage of
the probe exceeds a fixed level above baseline. For a chosen
threshold, a smaller starting copy number results in a higher
CT value. In this study, we chose GAPDH mRNA as an internal
control. The relative amount of tissue PlGF mRNA, stan-
dardized against the amount of GAPDHmRNA,was expressed
as DCT Z (PlGF CT e GAPDH CT). Then, the relative
expression level of tissue PlGF mRNA in each OSCC patients
was expressed as DCTZ (OSCC CT e non-OSCC CT).
Statistical analysis
The mean PlGF mRNA levels between OSCC and non-OSCC
tissues were compared by paired t-test. The correlation
between the PlGF mRNA levels in OSCC samples and clinico-
pathological parameters of OSCC patients was analyzed by
Student’s t-test. Cumulative survival was analyzed with the
Kaplan-Meier product-limit method. The duration of
recurrence-free survival wasmeasured from the beginning of
surgery to the time of recurrence (complete) or the last
follow-up (censored). Comparison of cumulative survival
between groups was performed using the log-rank test with
the Statistica program 7.0 (StatSoft Inc., Tulsa, OK, USA).
Univariate andmultivariate survival analyseswereperformed
with the Cox proportional hazard regression model to assess
additional prognostic values of the different variables using
SAS 9.1 (SAS Institute Inc., Morrisville, NC, USA). A p value of
less than 0.05 was considered statistically significant.
Results
PlGF mRNA levels in oral cancer tissues
The mean PlGF mRNA levels in the paired OSCC and non-
OSCC tissues of 63 OSCC patients are presented in Table 1.Table 1 Mean PlGF mRNA CT (threshold cycle) value in paired
Groups Mean PlGF mRNA CT value  S
Non-OSCC (n Z 63) 9.1  0.6
OSCC (n Z 63) 7.2  0.3
OSCCenon-OSCC (n Z 63)
a DCT Z (OSCC CT e non-OSCC CT).
* A significant difference in the mean PlGF mRNA CT value was f
p < 0.001.
PlGF Z placenta growth factor; OSCC Z oral squamous cell carcinomThe lower CT value is interpreted as having higher initial
copy numbers of PlGF mRNA in tissues. We found that the
mean PlGF mRNA CT value was significantly lower in OSCC
(7.2  0.3) than in control counterpart of non-OSCC tissues
(9.1  0.6, p < 0.001; Table 1).
Correlation between PlGF mRNA levels in OSCC
samples and clinicopathological parameters of
OSCC patients
In this study, the higher the DCT, the greater the copy
number of PlGF mRNA in tissues. Correlation between the
mean PlGF mRNA DCT value in 63 paired surgical samples
and clinicopathological parameters of 63 OSCC patients
is shown in Table 2. We found that the mean PlGF
mRNA DCT value was significantly higher in OSCC patients
with larger tumor size (p Z 0.030), positive lymph node
metastasis (p Z 0.003), more advanced clinical stages
(pZ 0.013), and the presence of loco-regional recurrence
(p Z 0.039; Table 2). No significant correlation was found
between the mean PlGF mRNA DCT value and patients’
age, sex, cancer location, and histology of OSCC. The PlGF
mRNA DCT value was also not associated with the areca
quid chewing, cigarette smoking, or alcohol drinking habit
(data not shown).
Survival analysis
Univariate analysis performed by Cox proportional hazard
regression model identified larger tumor size (p Z 0.027),
positive lymph node metastasis (p Z 0.003), advanced
clinical stage (p Z 0.032), and PlGF mRNA DCT value >2
(pZ 0.008, the median PlGF mRNA DCT value was 1.9) as
correlating with poorer survival of OSCC patients. Multi-
variate analyses with Cox regression model further identi-
fied positive lymph node metastasis (p Z 0.019) and PlGF
mRNA DCT value >2 (p Z 0.016) as two independent
unfavorable prognosis factors (Table 3). The Kaplan-Meier
curve showed that OSCC patients with a PlGF mRNA DCT
value >2 had a significantly poorer cumulative recurrence-
free survival than those with a PlGF mRNA DCT value of
2 (p Z 0.017, log-rank test, Fig. 1).
Discussion
In this study, we measured the PlGF mRNA level in 63 paired
OSCC and non-OSCC tissue samples. The relatively lower
mean PlGF mRNA CT value in OSCC than in non-OSCC tissues
indicated an increased PlGF mRNA expression in OSCCOSCC and non-OSCC tissue samples.
D Mean PlGF mRNAaDCT value  SD p value
1.9  0.7 <0.001*
ound between paired OSCC and non-OSCC tissue samples with
a.
Table 2 Correlation between mean PlGF mRNA DCT
values in 63 paired surgical samples and clinicopathological
parameters of 63 OSCC patients.
Mean PlGF mRNAa 
DCT value  SD
p value
Patients’ age (y)
50 (n Z 21) 1.4  1.1 0.537
>50 (n Z 42) 1.8  0.7
Patients’ sex
Men (n Z 59) 2.1  1.1 0.136
Women (n Z 4) 1.8  0.8
Cancer location
Buccal mucosa (n Z 23) 1.7  1.1 0.678
Tongue (n Z 19) 1.7  0.8
Other oral
mucosal sites (n Z 21)
1.8  1.1
T status
T1 þ T2 (n Z 39) 1.0  0.3 0.030
T3 þ T4 (n Z 24) 2.3  0.2
N status
N0 (n Z 41) 1.1  0.1 0.003
N1 þ N2 þ N3 (n Z 22) 2.5  0.3
Clinical staging
Stages 1 þ 2 (n Z 29) 1.1  0.2 0.013
Stages 3 þ 4 (n Z 34) 2.3  0.3
Loco-regional recurrence
Without (n Z 52) 1.2  0.2 0.039
With (n Z 11) 2.1  0.4
Histology of OSCC
Well differentiated
(n Z 59)
2.1  0.2 0.131
Moderately
differentiated (n Z 4)
1.8  0.5
a DCT Z (OSCC CT e non-OSCC CT).
PlGF Z placenta growth factor; OSCC Z oral squamous cell
carcinoma.
Figure 1 Kaplan-Meier survival curve showing relation
between tissue PlGF mRNA levels in 63 patients with OSCC and
recurrence-free survival in these 63 OSCC patients. The dura-
tion of recurrence-free survival was measured from the
beginning of surgery to the time of recurrence (complete) or
the last follow-up (censored). The cumulative recurrence-free
survival for patients with PlGF mRNA DCT value >2 was
significantly poorer than that for patients with PlGF mRNA
DCT value 2 (p Z 0.017, log-rank test). PlGF Z placenta
growth factor; OSCC Z oral squamous cell carcinoma.
256 S.-J. Cheng et al.tissues than in non-OSCC tissues. The finding of PlGF mRNA
expression in normal-looking oral mucosal (non-OSCC)
tissue adjacent to OSCC also suggests that the PlGF mRNA
expression is an early event in oral carcinogenesis.Table 3 Univariate and multivariate recurrence-free survival a
parameters in patients with OSCC by Cox proportional hazard reg
Factor
Univariate
T status (T1 þ T2 vs. T3 þ T4)
N status (N0 vs. N1 þ N2 þ N3)
Clinical stage (Stages 1 þ 2 vs. stages 3 þ 4)
PlGF mRNA DCT value (2.0 vs. >2.0)
Multivariate
N status (N0 vs. N1 þ N2 þ N3)
PlGF mRNA DCT value (2.0 vs. >2.0)
PlGF Z placenta growth factor; OSCC Z oral squamous cell carcinomTakahashi et al15 found a significantly higher PlGF mRNA
expression in hypervascular renal cell carcinoma tissues
than in adjacent normal kidney tissues. Chen et al8 re-
ported a significantly higher PlGF protein level in gastric
cancer tissues than in the corresponding non-cancerous
mucosal tissues. Parr et al7 also demonstrated that the
PlGF protein expression is dramatically increased in breast
cancer tissues compared with normal breast tissues. Actu-
ally, overexpression of PlGF mRNA or protein has been
demonstrated in a variety of human carcinomas including
breast,7 gastric,8 lung,9 colorectal,10 renal cell,15 uterine
cervical,16 and hepatocellular carcinomas.11
A significant association of higher PlGF mRNA and protein
levels with regional nodal metastasis of OSCC was shown in
the present and our previous studies.12 The similar findings
were also found in human breast cancer.7 The reasons why
PlGF increased cancer metastasis could be explained as
follows. First, angiogenesis is a pivotal factor for tumornalyses of the PlGF mRNA expression and clinicopathological
ression model.
Hazard ratio (95% CI) p value
6.049 (2.963e10.266) 0.027
11.552 (5.745e21.081) 0.003
5.349 (1.076e8.495) 0.032
9.275 (3.578e18.167) 0.008
8.294 (3.059e16.685) 0.019
7.285 (3.566e18.274) 0.016
a.
PlGF mRNA in oral cancer tissues 257growth and metastasis.17 PlGF can promote vessel growth
and maturation directly by affecting endothelial and mural
cells, as well as indirectly by recruiting pro-angiogenic cell
types.3 PlGF can also increase the expression of VEGFAwhich
is a potent angiogenic factor.3 Furthermore, PlGF displaces
VEGFA from FLT1, which liberates VEGFA and allows it to
activate FLK1 (also known as VEGFR2) and augment VEGF-
driven angiogenesis.18 PlGF also activates and attracts
macrophages that release angiogenic and lymphangiogenic
molecules.19 In addition, PlGF can promote tumor angio-
genesis, lymphangiogenesis, and the formation of the pre-
metastatic niche.3 Second, PlGF promotes the growth,
survival andmigration ofmetastatic tumor cells.3 Third, PlGF
enhances the expression of matrix metalloproteinase 9
(MMP9) which facilitates the cancer cell invasion and
metastasis.3 Fourth, PlGF directly regulates the motility of
human non-small cell lung cancer cells20 and also stimulates
in vitromotility and invasion of the human breast tumor cell
lines.21 Moreover, an antagonistic PlGF/FLT1 peptide can
inhibit the growth and metastasis of human breast cancer
xenografts.21 Fifth, PlGF inhibits the differentiation of
dendritic cells and in turn suppresses the antigen recognition
and anti-tumor immune defense.3 In summary, PlGF may
promote lymph node metastases through multiple mecha-
nisms such as an increase in tumor angiogenesis and lym-
phangiogenesis, an increase in tumor cell survival, motility,
migration and invasion, an elevated expression of MMP9, and
an inhibition of the immune surveillance by dendritic cells.
This study showed a significant association of PlGF mRNA
overexpression in OSCCs with larger tumor size and positive
lymph node metastasis. Because higher T and N statuses
always result in more advanced clinical stages of OSCC, it is
not difficult to explain why OSCCs with the higher expres-
sion of PlGF mRNA are prone to have the more advanced
clinical stages. Indeed, high expression of PlGF mRNA or
protein is significantly associated with an advanced clinical
stage of gastric,8 lung,9 and colorectal cancers.10
A significant correlation between the higher PlGF mRNA
expression (higher DCT value) in OSCCs and the poorer
recurrence-free survival in OSCC patients was demon-
strated in this study. In addition, PlGF mRNA DCT value >2
was identified as an independent unfavorable prognosis
factor by multivariate analyses with Cox regression model.
Previous study also showed a significant association of
higher level of PlGF mRNA with a shorter survival in patients
with colorectal carcinoma.10 In addition, an increased level
of PlGF protein is significantly related to poor prognosis in
patients with breast7 or gastric carcinomas.8 Furthermore,
high PlGF protein or mRNA level is significantly associated
with recurrence of breast cancer.7 PlGF protein or mRNA
level can also predict the early recurrence after radical
resection of hepatocellular carcinoma.11 The above findings
indicate that PlGF protein or mRNA level may be an
important prognostic indicator for patients with certain
types of human carcinomas, including OSCC.
Our results showed a significant increase in the PlGF
mRNA expression in OSCC tissues compared to that in non-
OSCC tissues. We also found that the PlGF mRNA level in
OSCC samples was significantly correlated with tumor size,
N status, clinical staging, and locoregional recurrence of
OSCCs. Moreover, OSCC patients with a higher PlGF mRNA
expression had a poorer cumulative recurrence-freesurvival than those with lower PlGF mRNA levels. PlGF
mRNA DCT value >2 were also identified as an indepen-
dent unfavorable prognosis factors for OSCCs by multivar-
iate analyses. These results indicate that the PlGF mRNA
level may be a biomarker for prediction of the progression
of OSCCs and the prognosis of OSCC patients in Taiwan.
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